AbCellera Biologics Inc vs Norfolk Southern Corporation — how do they compare? AbCellera Biologics Inc trades at $9.21 (market cap $2.99B), while Norfolk Southern Corporation trades at $334 (market cap $75.15B). The key difference: Norfolk Southern Corporation is far larger — about 25.1× AbCellera Biologics Inc's market cap, and Norfolk Southern Corporation pays a 1.61% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | NSC | |
|---|---|---|
Market Cap | $2.99B | $75.15B |
Sector | Health | Technology |
52-Week High | $9.76 | $350.66 |
52-Week Low | $2.78 | $272.35 |
Enterprise Value | $2.58B | $90.70B |
Dividend Yield | — | 1.61% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Norfolk Southern Corporation is a major North American railroad company operating one of the largest freight rail networks in the eastern United States. The company transports a diverse range of commodities, including coal, intermodal containers, and various industrial products. NSC is a critical link in the nation's supply chain, providing efficient, long-haul transportation services to and from ports and industrial centers.
Read more on NSC →